Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof

US11136296B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hartmut Beck · Wuppertal, DE
• Raimund Kast · Wuppertal, DE
• Mark Meininghaus · Wuppertal, DE
• Lisa DIETZ · Wuppertal, DE
• Chantal Fuerstner · Neheim, DE
• Timo Stellfeld · Berlin, DE
• Sonja Anlauf · Wuppertal, DE
• Clemens-Jeremias Von Buehler · Neuss, DE
• Michaela BAIRLEIN · Wuppertal, DE
• Johanna Anlahr · Dortmund, DE
• Uwe Muenster · Wuppertal, DE
• Carsten TERJUNG · Bochum, DE
• Hannah Joerissen · Heiligenhaus, DE
• Peter Hauff · Berlin, DE
• Joerg Mueller · Berlin, DE
• Karoline Droebner · Velbert, DE
• Jens Nagel · Daxweiler, DE

Key dates

• Filing date: Apr 4, 2018
• Grant date: Oct 5, 2021
• Expiry date: Jul 12, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.